HEALTH● LOWOct 5 · Oct 5, 2026, 7:42 PM
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment
Seeking Alpha Tech · global
Data from Genmab and AbbVie has enhanced the standing of Epkinly as a potential first-line treatment for B-cell lymphoma. This development indicates progress in cancer therapy options.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH44m agoLaura Carmona, yoga expert, explains why this discipline is much more than stretching: "It requires strength, control, mobility and a lot of concentration"ClarínHEALTH1h agoSymptoms of cancer in children are not always easy to spot: here are the signs to watch out forBBC AfriqueHEALTH1h agoWHO alarmed that many Ebola deaths in DR Congo occur in communitiesAfricanews [en]HEALTH1h agoNo evidence of suspected plague outbreak in Russia, says WHOVanguard Nigeria